Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study
The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions).
- Status
- planned
- Phase
- Phase 1
- Institution
- Oregon Health and Science University
- Start date
- 2026-01-01
- End date
- 2026-12-31
- Registry ID
- NCT06988319
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.